PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
So this a Phase I study with primary objective to determine the feasibility and safety of
combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin
and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell
transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic
GVHD, progression-free survival , and overall survival